Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

By afschroeder • September 6, 2026

Hoffman R, Watanabe M, Martínez E, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Lu AB, Aberg JA, Currier JS, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis. Open Forum Infect Dis. 2026 Aug 20;13(9):ofag507. doi: 10.1093/ofid/ofag507. PMID: 42699213; PMCID: PMC13542724.

Tags: Cardiology/Epi, cardiovascular disease, HIV, Hypertension, hypertension control, Infectious Diseases, Publications

Heart failure and atrial fibrillation prediction from non-gated chest CT scans using AI-based cardiac chamber volumetry: an AI-CVD study within the multi-ethnic study of atherosclerosis (MESA)

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]

The clinical significance of baseline lung allograft dysfunction in single and bilateral lung transplant recipients

Lari SM, Liang H, Dadfar B, Zhou J, Kim J, Sayah D, Der Hovanessian A, Saggar R, Shino MY, Turner G, Amubieya O, Haddad T,[...]

Echocardiographic estimates of pulmonary artery acceleration time and mortality risk in older adults

Nations JA, Mordini FE, Khosla R, Lam PH, Frishman WH, Aronow WS, Bytyçi I, Böhm M, Aldabain L, Vyas K, Mashaal H, Zhang S, Morgan[...]